Products Categories
CAS No.: | 5034-77-5 |
---|---|
Name: | Imidazole |
Article Data: | 2 |
Molecular Structure: | |
Formula: | C8H12 Cl2 N6 O |
Molecular Weight: | 279.129 |
Synonyms: | Imidazole-4(or5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]- (7CI); Imidazole-4-carboxamide,5-[3,3-bis(2-chloroethyl)-1-triazeno]- (8CI); 5(or4)-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide;5-[3,3-Bis(2-chlorethyl)-1-triazeno]imidazole-4-carboxamide;5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide;5-[3,3-Bis(2-chloroethyl)-1-triazenyl]imidazole-4-carboxamide;5-[3,3-Bis(2-chloroethyl)triazeno]imidazole-4-carboxamide; BIC; Imidazolemustard; NSC 82196 |
Density: | 1.59g/cm3 |
Boiling Point: | 415.2°Cat760mmHg |
Flash Point: | 204.9°C |
Safety: | Suspected carcinogen with experimental neoplastigenic and tumorigenic data. Poison by ingestion and intraperitoneal routes. Experimental teratogenic effects. Human systemic effects by intravenous route: nausea. When heated to decomposition it emits very toxic fumes of Cl− and NOx. |
PSA: | 99.73000 |
LogP: | 1.98720 |
IUPAC Name: 4-[(E)-bis(2-chloroethyl)aminodiazenyl]-4H-imidazole-5-carboxamide
Synonyms of Imidazole mustard (CAS NO.5034-77-5) : 1H-Imidazole-4-carboxamide, 5-(3,3-bis(2-chloroethyl)-1-triazenyl)- (9CI) ; Imidazole-4-carboxamide, 5-(3,3-bis(2-chloroethyl)-1-triazeno)- ; 5-(3,3-Bis(2-Chlorethyl)-1-triazeno)-imidazole-4-carboxamide ; 5-(3,3-Bis(2-Chloroethyl)-1-triazeno)imidazole-4-carboxamide
InChI:InChI=1/C8H12Cl2N6O/c9-1-3-16(4-2-10)15-14-8-6(7(11)17)12-5-13-8/h5,8H,1-4H2,(H2,11,17)/b15-14+
CAS NO: 5034-77-5
Molecular Formula:C8H12Cl2N6O
Molecular Weight :279.1265
Molecular Structure :
Index of Refraction: 1.663
Surface Tension: 62.1 dyne/cm
Density: 1.59 g/cm3
Flash Point: 213 °C
Enthalpy of Vaporization: 68.38 kJ/mol
Boiling Point: 428.6 °C at 760 mmHg
Vapour Pressure: 1.49E-07 mmHg at 25°C
Imidazole mustard (CAS NO.5034-77-5) is used as intermediate in organic synthesis.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
human | TDLo | intravenous | 9gm/kg (9000mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING | Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 671, 1972. |
mouse | LD50 | intraperitoneal | 60060ug/kg (60.06mg/kg) | National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986, | |
rat | LD50 | intraperitoneal | 210mg/kg (210mg/kg) | National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986, | |
rat | LD50 | oral | 267mg/kg (267mg/kg) | National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986, |
NCI Carcinogenesis Studies (ipr); Clear Evidence: mouse, rat CANCAR Cancer. 40 (1977),1935. .
Suspected carcinogen with experimental neoplastigenic and tumorigenic data. Poison by ingestion and intraperitoneal routes. Experimental teratogenic effects. Human systemic effects by intravenous route: nausea. When Imidazole mustard (CAS NO.5034-77-5) is heated to decomposition, it emits very toxic fumes of Cl− and NOx.